Madopar (Benserazide Hydrochloride, Levodopa)

• Madopar acts on the dopaminergic pathway and is indicated for Parkinsonian disorders.
• Parkinson's disease: improves motor function and reduces rigidity and bradykinesia.
• Parkinsonian syndrome: alleviates tremor and stiffness associated with secondary parkinsonism.
• Early-stage Parkinson's disease: provides symptomatic relief to maintain daily activities.

• Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine, replenishing depleted central dopamine stores. Benserazide, a peripheral aromatic L‑amino‑acid decarboxylase inhibitor, blocks conversion of levodopa outside the brain, increasing its availability for central conversion and minimizing peripheral side effects such as nausea and cardiovascular effects. The combined formulation allows lower levodopa doses while achieving therapeutic plasma concentrations, and the increased central dopamine stimulates D1 and D2 receptors to improve motor control.

Madopar may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Nausea and vomiting
• Dizziness or light‑headedness
• Orthostatic hypotension
• Headache
• Insomnia
• Dry mouth

Serious or Rare Side Effects

• Dyskinesia (involuntary movements)
• Hallucinations or other psychiatric disturbances
• Severe hypotension or cardiac arrhythmia

• When prescribing Madopar, clinicians should observe several precautionary measures to ensure safe use.
• Monitor blood pressure: watch for orthostatic hypotension, especially at treatment initiation.
• Assess for dyskinesia: adjust dose if involuntary movements develop.
• Review concomitant MAO‑B inhibitors: avoid combined use due to risk of hypertensive crisis.
• Adjust dose in renal impairment: reduced clearance may increase plasma levels.
• Avoid abrupt discontinuation: taper gradually to prevent withdrawal symptoms.
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Madopar interacts with several medicines; some combinations must be avoided while others require careful monitoring.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): can cause severe hypertensive reactions.
• Antipsychotics that block dopamine receptors (e.g., haloperidol): reduce therapeutic effect and may precipitate neuroleptic malignant syndrome.

Moderate Interactions (Monitor Closely)

• Iron or calcium supplements: decrease levodopa absorption; separate dosing by at least 2 hours.
• High‑protein meals: compete with levodopa transport, potentially lowering efficacy.
• Anticholinergic agents (e.g., benztropine): may increase central side effects such as confusion.